BenevolentAI has announced it will be reducing headcount by around 30% and closing its US office as part of a change of focus in its business priorities. The company says it will focus on its AI-driven drug discovery collaboration and proprietary pipeline, believing these will bring the greatest potential return for shareholders. Work on the […]